权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Predicting Adjuvant Chemotherapy Response in Lung Cancer

预测肺癌辅助化疗反应

基本信息

批准号：
8617729
负责人：
Yang Xie
金额：
$ 32.72万
依托单位：
UT SOUTHWESTERN MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-09-01 至 2016-02-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8617729
关键词：
Accounting Adjuvant Chemotherapy Adopted Adverse effects Area Under Curve Cancer Center Cancer Patient Cause of Death Cessation of life Chemotherapy-Oncologic Procedure Clinical Clinical Data Clinical Research Copy Number Polymorphism DNA copy number Data Data Analyses Data Set Decision Making Dimensions Disease-Free Survival Epidemiology Evaluation Excision Genes Genetic Polymorphism Goals Histology Individual Joints Knowledge Lead Literature Lung Malignant Neoplasms Malignant neoplasm of lung Medical Oncology Medicine Messenger RNA Methodology Methods Modeling Molecular Profiling Non-Small-Cell Lung Carcinoma Outcome Pathological Staging Pathology Patients Performance Receiver Operating Characteristics Recurrence Research Resected Resistance Risk Sampling Selection for Treatments Staging Subgroup Survival Rate Texas Time Tissue Banking Tissue Banks Translational Research Translations Tumor-Derived United States Universities Weight Woman anticancer research base cancer therapy chemotherapy clinical decision-making clinical epidemiology clinical practice cohort drug sensitivity epidemiologic data follow-up genetic epidemiology genome-wide improved mRNA Expression men novel pre-clinical programs protein expression public health relevance randomized trial response standard of care

项目摘要

DESCRIPTION (provided by applicant): Project Summary: Lung Cancer is the leading cause of death from cancer in the United States. Adjuvant chemotherapy is increasingly used as the standard of care for patients with resected Non-Small-Cell Lung Cancer (NSCLC). However, such treatment is also associated with serious adverse effects. A large amount of drug sensitivity data, as well as clinical, epidemiology and genome-wide molecular profiling data have been collected by The University of Texas Specialized Program in Research Excellence (UT SPORE) in Lung Cancer to develop personalized cancer treatments. However, the integration and translation of these massive data to scientific knowledge and clinical usage has become a bottleneck of current cancer research. This study aims at tackling this problem and building a comprehensive prediction model of response to adjuvant chemotherapy in lung cancer. We will use the existing preclinical, clinical and epidemiology data to develop a comprehensive prediction model. We will collaborate with UT SPORE in Lung Cancer to collect new data on an independent patient cohort to validate the model. The specific aims of this study are: (1) To develop and compare predictive signatures from individual molecular profiling datasets including mRNA expression, protein expression, copy number variation and germline polymorphism data. (2) To build a comprehensive prediction model of response to adjuvant chemotherapy by integrating predictive molecular signatures and clinical information. (3) To validate and characterize the comprehensive prediction model using an independent patient cohort. This project assembles an outstanding research team with complementary expertise in quantitative research, clinical research, translational research, pathology and genetic epidemiology, and is dedicated to improving lung cancer treatments. If implemented successfully, this project will have substantial impact on lung cancer clinical practice and translational cancer research.

描述（由申请人提供）：项目概述：肺癌是美国癌症死亡的主要原因。辅助化疗越来越多地被用作切除的非小细胞肺癌（NSCLC）患者的标准治疗。然而，这种治疗也与严重的不良反应有关。大量的药物敏感性数据，以及临床，流行病学和全基因组分子谱数据已被德克萨斯大学肺癌卓越研究专业计划（UT SPORE）收集，以开发个性化的癌症治疗。然而，如何将这些海量数据整合并转化为科学知识和临床应用已成为当前癌症研究的瓶颈。本研究旨在解决这一问题，并建立一个综合的预测模型，辅助化疗对肺癌的反应。我们将利用现有的临床前、临床和流行病学数据来开发一个全面的预测模型。我们将与UT SPORE在肺癌领域合作，收集独立患者队列的新数据，以验证该模型。本研究的具体目的是：（1）从单个分子谱数据集（包括mRNA表达、蛋白质表达、拷贝数变异和生殖系多态性数据）开发和比较预测特征。(2)结合预测分子标记和临床信息，建立辅助化疗反应的综合预测模型。(3)使用独立患者队列验证和表征综合预测模型。该项目汇集了一支优秀的研究团队，在定量研究，临床研究，转化研究，病理学和遗传流行病学方面具有互补的专业知识，并致力于改善肺癌治疗。如果成功实施，该项目将对肺癌临床实践和转化癌症研究产生重大影响。